Skin cancer, a major public health issue
Skin cancer is the most common form of cancer worldwilde among caucasian populations.
Between 1980 and 2005, there was a threefold increase in the incidence of both non-melanoma and melanoma skin cancers. Globally, there are approximately two to three million new non-melanoma skin cancer diagnoses and 132,000 new melanoma diagnoses each year.
• Though early diagnosis is critical for survival, about one out of every three melanomas are missed at initial diagnosis.
• More than 50% of biopsies are later proven to be useless, leaving unnecessary scars.
• The entire process of sampling and histological analysis is time-consuming, taking up to one month.
A new look under your skin
DAMAE Medical has developed an innovative technology called OCTAV providing dermatologists with a new in vivo imaging modality capable of producing in-depth images of the tissue, similar to histology without the need for skin tissue excision and processing.
OCTAV provides microscopic evaluation of the lesion in real time, without sampling.
Winner of the world innovation competition
DAMAE Medical has been recognized by the French Innovation 2030 Commission, being one of the winners of the Worldwide Innovation Challenge in the category “Individualized Medecine”.
On July 13th 2014, cofounders Anaïs Barut and David Siret had the honor of being welcomed at the French Palais de L’Elysée. Here, they presented DAMAE Medical to President François Hollande, esteemed government ministers, and the Head of the Innovation 2030 Commission, Mrs. Anne Lauvergeon.
the team and its partners
Working together since January 2013, the three fondators of DAMAE Medical, each experts in their respective fields, constitute a pluridisciplinar, coherent and complementary leading team. To achieve the integration of the company’s devices in the medical sector, the leading team is regularly advised and guided by a diversely qualified team of partners.